The estimated Net Worth of Tasos Konidaris is at least $5.52 Milion dollars as of 12 March 2024. Mr. Konidaris owns over 87,720 units of Kadmon Inc stock worth over $5,302,007 and over the last 12 years he sold KDMN stock worth over $0. In addition, he makes $217,500 as Non-Executive Independent Chairman of the Board at Kadmon Inc.
Sign up
Mr. Konidaris KDMN stock SEC Form 4 insiders trading
Tasos has made over 8 trades of the Kadmon Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 87,720 units of KDMN stock worth $833,340 on 12 March 2024.
The largest trade he's ever made was exercising 138,826 units of Kadmon Inc stock on 1 March 2024 worth over $1,318,847. On average, Tasos trades about 28,923 units every 52 days since 2012. As of 12 March 2024 he still owns at least 558,106 units of Kadmon Inc stock.
You can see the complete history of Mr. Konidaris stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tasos Konidaris biography
Tasos G. Konidaris serves as Non-Executive Independent Chairman of the Board of the Company. Mr. Konidaris has served as Senior Vice President, Chief Financial Officer of Amneal Pharmaceuticals, Inc. since March 2020. He previously served as Executive Vice President and Chief Financial Officer of Alcresta Therapeutics, Inc. Prior to that, Mr. Konidaris served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria, Inc., a biotherapeutics company, from 2011 to 2015. Prior to joining Ikaria, since 2007, Mr. Konidaris served as Senior Vice President and Chief Financial Officer at Dun & Bradstreet (D&B) Corporation, a leading commercial information services company, and previously held financial and general management roles of increasing responsibility at Schering-Plough Corporation, Pharmacia Corporation, Novartis Corporation and Bristol-Myers Squibb. Mr. Konidaris currently serves on the board of Zep, Inc. Mr. Konidaris holds an MBA from Drexel University and a B.S. from Gwynedd Mercy College.
What is the salary of Tasos Konidaris?
As the Non-Executive Independent Chairman of the Board of Kadmon Inc, the total compensation of Tasos Konidaris at Kadmon Inc is $217,500. There are 9 executives at Kadmon Inc getting paid more, with Harlan Waksal having the highest compensation of $4,742,770.
How old is Tasos Konidaris?
Tasos Konidaris is 53, he's been the Non-Executive Independent Chairman of the Board of Kadmon Inc since 2019. There are 8 older and 2 younger executives at Kadmon Inc. The oldest executive at Kadmon Holdings Inc is Eugene Bauer, 77, who is the Independent Director.
What's Tasos Konidaris's mailing address?
Tasos's mailing address filed with the SEC is C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807.
Insiders trading at Kadmon Inc
Over the last 8 years, insiders at Kadmon Inc have traded over $7,020,661 worth of Kadmon Inc stock and bought 7,084,916 units worth $54,943,934 . The most active insiders traders include Advisors Llcperceptive Life..., Asset Management Lp Golden ... a Daniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,948,175. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth $46,880.
What does Kadmon Inc do?
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
What does Kadmon Inc's logo look like?
Complete history of Mr. Konidaris stock trades at Kadmon Inc a Amneal Pharmaceuticals Inc
Kadmon Inc executives and stock owners
Kadmon Inc executives and other stock owners filed with the SEC include:
-
Harlan Waksal,
President, Chief Executive Officer, Director -
Steven Meehan,
Chief Financial Officer, Executive Vice President -
Gregory Moss,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Dr. Harlan W. Waksal,
Pres, CEO & Director -
Gregory S. Moss Esq.,
Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Arthur Kirsch,
Independent Director -
David Cohen,
Independent Director -
Cynthia Schwalm,
Independent Director -
Eugene Bauer,
Independent Director -
Tasos Konidaris,
Non-Executive Independent Chairman of the Board -
Ellen Cavaleri,
IR Contact Officer -
Nancy Miller-Rich,
Director -
John Ryan,
Executive Vice President, Chief Medical Officer -
Dr. Simon Cooper,
Sr. VP & Chief Medical Officer -
Haya Taitel M.S., R.Ph.,
Sr. VP & Chief Commercial Officer -
Sanjay Aggarwal,
Sr. VP of Clinical Devel. -
Kyle Carver,
Sr. VP, Chief Accounting Officer & Controller -
Charles Darder,
Principle Accounting Officer -
Asset Management Lp Golden ...,
-
D. Dixon Boardman,
-
Konstantin Poukalov,
EVP, Chief Financial Officer -
Alexandria Forbes,
-
Andrew B Cohen,
-
I, Llc Kadmon,
-
Susan Wiviott,
-
Shengda Zan,
-
Thomas E Shenk,
-
Steven N. Gordon,
Exec VP, GC, Chief Admin, Comp -
Lawrence Kenneth Cohen,
Exec. VP, Business Develop. -
Daniel S Third Point Llc Loeb,
-
Bart M Schwartz,
-
Advisors Llcperceptive Life...,
-
Kyle Carver,
SVP, CAO, Controller -
Cynthia Louise Flowers,
Director